Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.

Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, Stefanovic A, Bernstein SH, Weitman S, Karnad A, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D.

Clin Cancer Res. 2018 Dec 15;24(24):6150-6159. doi: 10.1158/1078-0432.CCR-18-0286. Epub 2018 Aug 6.

PMID:
30082475
2.

Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort.

Rimsza LM, Li H, Braziel RM, Spier CM, Persky DO, Dunlap J, LeBlanc M, Bartlett N, Leonard JP, Smith SM, Press OW, Friedberg JW.

Haematologica. 2018 Apr;103(4):e151-e153. doi: 10.3324/haematol.2017.175059. Epub 2018 Feb 22. No abstract available.

3.

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW.

J Clin Oncol. 2018 Mar 1;36(7):697-703. doi: 10.1200/JCO.2017.74.5083. Epub 2018 Jan 22.

4.

Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.

Islam S, Vick E, Huber B, Morales C, Spier C, Cooke L, Weterings E, Mahadevan D.

Oncotarget. 2017 Nov 1;8(59):100326-100338. doi: 10.18632/oncotarget.22222. eCollection 2017 Nov 21.

5.

Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas.

Islam S, Qi W, Morales C, Cooke L, Spier C, Weterings E, Mahadevan D.

Mol Cancer Ther. 2017 Oct;16(10):2083-2093. doi: 10.1158/1535-7163.MCT-17-0089. Epub 2017 Jun 14.

6.

Evaluation of watershed-derived mass loads to prioritize TMDL decision-making.

Gulati S, Stubblefield AA, Hanlon JS, Spier CL, Camarillo MK, Stringfellow WT.

Water Sci Technol. 2016;73(3):654-61. doi: 10.2166/wst.2015.530.

7.

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW.

J Clin Oncol. 2015 Jul 20;33(21):2399-404. doi: 10.1200/JCO.2014.60.6327. Epub 2015 Jun 15.

8.

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.

Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI.

Blood. 2015 Jan 8;125(2):236-41. doi: 10.1182/blood-2014-06-584623. Epub 2014 Nov 13.

9.

Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models.

Chen LQ, Howison CM, Spier C, Stopeck AT, Malm SW, Pagel MD, Baker AF.

Leuk Lymphoma. 2015 May;56(5):1432-9. doi: 10.3109/10428194.2014.933218. Epub 2014 Nov 10.

10.

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.

Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM.

Blood. 2014 Aug 21;124(8):1259-65. doi: 10.1182/blood-2014-04-570044. Epub 2014 Jul 11.

11.

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.

Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, LeBlanc ML, Rimsza LM, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Slager SL, Persky DO, Miller TP, Fisher RI, Ambrosone CB, Briehl MM.

Am J Hematol. 2014 Jun;89(6):639-45. doi: 10.1002/ajh.23709. Epub 2014 Apr 12.

12.

Use of continuous and grab sample data for calculating total maximum daily load (TMDL) in agricultural watersheds.

Gulati S, Stubblefield AA, Hanlon JS, Spier CL, Stringfellow WT.

Chemosphere. 2014 Mar;99:81-8. doi: 10.1016/j.chemosphere.2013.10.026. Epub 2013 Nov 13.

PMID:
24238914
13.

A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.

Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI.

Clin Cancer Res. 2013 Dec 1;19(23):6624-32. doi: 10.1158/1078-0432.CCR-13-1120. Epub 2013 Oct 15.

14.

Impact of co-digestion on existing salt and nutrient mass balances for a full-scale dairy energy project.

Camarillo MK, Stringfellow WT, Spier CL, Hanlon JS, Domen JK.

J Environ Manage. 2013 Oct 15;128:233-42. doi: 10.1016/j.jenvman.2013.04.060. Epub 2013 Jun 7.

PMID:
23747374
15.

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI.

J Clin Oncol. 2013 Jan 20;31(3):314-20. doi: 10.1200/JCO.2012.42.4101. Epub 2012 Dec 10.

16.

Distribution of hydrocarbons released during the 2010 MC252 oil spill in deep offshore waters.

Spier C, Stringfellow WT, Hazen TC, Conrad M.

Environ Pollut. 2013 Feb;173:224-30. doi: 10.1016/j.envpol.2012.10.019. Epub 2012 Nov 29.

PMID:
23202654
17.

Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.

Qi W, Spier C, Liu X, Agarwal A, Cooke LS, Persky DO, Chen D, Miller TP, Mahadevan D.

Leuk Res. 2013 Apr;37(4):434-9. doi: 10.1016/j.leukres.2012.10.017. Epub 2012 Nov 12.

18.

Sizing mitigation wetlands in agricultural watersheds.

Stringfellow WT, Karpuzcu ME, Spier C, Hanlon JS, Graham J.

Water Sci Technol. 2013;67(1):40-6. doi: 10.2166/wst.2012.527.

PMID:
23128619
19.

Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.

Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, Fisher RI, Miller TP.

Cancer. 2013 Jan 15;119(2):371-9. doi: 10.1002/cncr.27733. Epub 2012 Jul 25.

20.

Bioactivity-based screening methods for antibiotics residues: a comparative study of commercial and in-house developed kits.

Hoff R, Ribarcki F, Zancanaro I, Castellano L, Spier C, Barreto F, Fonseca SH.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2012;29(4):577-86. doi: 10.1080/19440049.2011.641508. Epub 2012 Jan 3.

PMID:
22214488
21.

Near real-time, on-site, quantitative analysis of PAHs in the aqueous environment using an antibody-based biosensor.

Spier CR, Vadas GG, Kaattari SL, Unger MA.

Environ Toxicol Chem. 2011 Jul;30(7):1557-63. doi: 10.1002/etc.546. Epub 2011 May 5.

PMID:
21547938
22.

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.

Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T.

J Clin Oncol. 2011 Jan 10;29(2):142-8. doi: 10.1200/JCO.2010.30.2729. Epub 2010 Dec 6.

23.

Deep-sea oil plume enriches indigenous oil-degrading bacteria.

Hazen TC, Dubinsky EA, DeSantis TZ, Andersen GL, Piceno YM, Singh N, Jansson JK, Probst A, Borglin SE, Fortney JL, Stringfellow WT, Bill M, Conrad ME, Tom LM, Chavarria KL, Alusi TR, Lamendella R, Joyner DC, Spier C, Baelum J, Auer M, Zemla ML, Chakraborty R, Sonnenthal EL, D'haeseleer P, Holman HY, Osman S, Lu Z, Van Nostrand JD, Deng Y, Zhou J, Mason OU.

Science. 2010 Oct 8;330(6001):204-8. doi: 10.1126/science.1195979. Epub 2010 Aug 24.

24.

Histopathology and immunophenotype of the spleen during acute antibody-mediated rejection.

Kaplan B, Jie T, Diana R, Renz J, Whinery A, Stubbs N, Bracamonte E, Spier C, Schubart P, Rilo H, Gruessner R.

Am J Transplant. 2010 May;10(5):1316-20. doi: 10.1111/j.1600-6143.2010.03067.x. Epub 2010 Mar 19.

25.

The development and evaluation of monoclonal antibodies for the detection of polycyclic aromatic hydrocarbons.

Spier CR, Bromage ES, Harris TM, Unger MA, Kaattari SL.

Anal Biochem. 2009 Apr 15;387(2):287-93. doi: 10.1016/j.ab.2009.01.020. Epub 2009 Jan 21.

PMID:
19344658
26.

Gene Expression and Serum Cytokine Profiling of Low Stage CLL Identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as Regulators of Cell Proliferation, Survival and Migration.

Mahadevan D, Choi J, Cooke L, Simons B, Riley C, Klinkhammer T, Sud R, Maddipoti S, Hehn S, Garewal H, Spier C.

Hum Genomics Proteomics. 2009 Jun 24;2009:453634. doi: 10.4061/2009/453634.

27.

Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.

Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP; Southwest Oncology Group.

J Clin Oncol. 2008 May 10;26(14):2258-63. doi: 10.1200/JCO.2007.13.6929. Epub 2008 Apr 14.

PMID:
18413640
28.

Diffuse aggressive histologies of non-hodgkin lymphoma: treatment and biology of limited disease.

Miller TP, Spier CM, Rimsza L.

Semin Hematol. 2006 Oct;43(4):207-12. Review.

PMID:
17027654
29.

Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures.

Mahadevan D, Spier C, Della Croce K, Miller S, George B, Riley C, Warner S, Grogan TM, Miller TP.

Mol Cancer Ther. 2005 Dec;4(12):1867-79.

30.

Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.

Galanis E, Burch PA, Richardson RL, Lewis B, Pitot HC, Frytak S, Spier C, Akporiaye ET, Peethambaram PP, Kaur JS, Okuno SH, Unni KK, Rubin J.

Cancer. 2004 Dec 1;101(11):2557-66.

31.

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.

Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, Delabie J, Rosenwald A, Staudt LM, Grogan TM.

Blood. 2004 Jun 1;103(11):4251-8. Epub 2004 Feb 19.

PMID:
14976040
32.

Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast.

Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, Hersh EM.

J Immunol. 2002 Aug 15;169(4):1829-36.

33.

Successful renal transplant outcome after intravenous gamma-globulin treatment of a highly sensitized pediatric recipient.

Al-Uzri AY, Seltz B, Yorgin PD, Spier CM, Andreoni K.

Pediatr Transplant. 2002 Apr;6(2):161-5.

PMID:
12000474
34.

The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features.

Braziel RM, Arber DA, Slovak ML, Gulley ML, Spier C, Kjeldsberg C, Unger J, Miller TP, Tubbs R, Leith C, Fisher RI, Grogan TM.

Blood. 2001 Jun 15;97(12):3713-20.

PMID:
11389007
35.

Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.

Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J, Weinberger B, Schiller G, Pearce T, Litchman M, Dalton W, Roe D, List AF.

J Clin Oncol. 2001 Mar 15;19(6):1589-99. Erratum in: J Clin Oncol 2001 May 1;19(9):2583.

PMID:
11250987
36.

Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.

Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, Akporiaye ET, Rinehart JJ, Edmonson J, Sobol RE, Forscher C, Sondak VK, Lewis BD, Unger EC, O'Driscoll M, Selk L, Rubin J.

J Clin Oncol. 1999 Oct;17(10):3313-23.

PMID:
10506635
37.

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.

Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI.

N Engl J Med. 1998 Jul 2;339(1):21-6.

38.

Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.

List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS.

Blood. 1996 Mar 15;87(6):2464-9.

PMID:
8630412
39.

Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML).

Samdani A, Vijapurkar U, Grimm MA, Spier CS, Grogan TM, Glinsmann-Gibson BJ, List AF.

Leuk Res. 1996 Feb;20(2):175-80.

PMID:
8628017
40.

Generation of cytotoxic effector cells against human melanoma.

Leong SP, Zhou YM, Granberry ME, Wang TF, Grogan TM, Spier C, White R, Mehta A, Lin AY.

Cancer Immunol Immunother. 1995 Jun;40(6):397-409.

PMID:
7627996
41.

Recurrent leg ulcerations as the initial clinical manifestation of Klinefelter's syndrome.

Spier C, Shear NH, Lester RS.

Arch Dermatol. 1995 Feb;131(2):230. No abstract available.

PMID:
7857129
42.
43.

Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome.

Glinsmann-Gibson B, Spier C, Baier M, Taetle R, Broudy VC, List AF.

Leukemia. 1994 May;8(5):827-32.

PMID:
7514248
44.

Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial.

Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani BN, et al.

Blood. 1994 Mar 15;83(6):1460-6.

PMID:
8123837
45.

NCAM (CD56)-positive malignant lymphoma.

Kern WF, Spier CM, Miller TP, Grogan TM.

Leuk Lymphoma. 1993 Dec;12(1-2):1-10. Review.

PMID:
7512851
46.

Expression of the EVI1 gene in chronic myelogenous leukemia in blast crisis.

Russell M, Thompson F, Spier C, Taetle R.

Leukemia. 1993 Oct;7(10):1654-7.

PMID:
8412328
47.

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W.

J Clin Oncol. 1993 Sep;11(9):1652-60.

PMID:
8102639
48.

Isolated ocular involvement in non-Hodgkin's lymphoma with immunocytochemical evaluation.

Allinson RW, Stanko ML, Aguirre ML, Spier CM, Kramer TR, Metrikin D.

Ann Ophthalmol. 1993 Mar;25(3):85-8.

PMID:
8460884
49.
50.

P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy.

Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ, Dalton WS.

Blood. 1993 Jan 15;81(2):490-5.

PMID:
8093668

Supplemental Content

Support Center